Susquehanna International Group’s Myriad Genetics MYGN Stock Holding History

Susquehanna International Group’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,900	Closed	-$436K	–	12859
2024 Q3	$436K	Sell	15,900 -7,300	-31%	-$198K	﹤0.01%	8798
2024 Q2	$567K	Buy	+23,200	New	+$509K	﹤0.01%	7951
2022 Q4	–	Sell	-35,900	Closed	-$685K	–	13236
2022 Q3	$685K	Buy	35,900 +18,200	+103%	+$418K	﹤0.01%	7624
2022 Q2	$322K	Buy	+17,700	New	+$368K	﹤0.01%	9393
2022 Q1	–	Sell	-13,400	Closed	-$370K	–	13627
2021 Q4	$370K	Sell	13,400 -6,700	-33%	-$194K	﹤0.01%	9981
2021 Q3	$649K	Sell	20,100 -100	-0.5%	-$3.32K	﹤0.01%	8715
2021 Q2	$618K	Sell	20,200 -2,200	-10%	-$63.6K	﹤0.01%	9060
2021 Q1	$682K	Sell	22,400 -7,900	-26%	-$224K	﹤0.01%	8737
2020 Q4	$599K	Sell	30,300 -4,800	-14%	-$77.5K	﹤0.01%	7891
2020 Q3	$458K	Sell	35,100 -15,500	-31%	-$196K	﹤0.01%	7860
2020 Q2	$574K	Sell	50,600 -6,900	-12%	-$98K	﹤0.01%	7088
2020 Q1	$823K	Sell	57,500 -9,000	-14%	-$190K	﹤0.01%	5827
2019 Q4	$1.81M	Sell	66,500 -43,600	-40%	-$1.2M	﹤0.01%	4488
2019 Q3	$3.15M	Buy	110,100 +16,600	+18%	+$484K	﹤0.01%	3412
2019 Q2	$2.6M	Sell	93,500 -4,500	-5%	-$127K	﹤0.01%	3690
2019 Q1	$3.25M	Buy	98,000 +73,600	+302%	+$2.24M	﹤0.01%	3020
2018 Q4	$709K	Sell	24,400 -26,000	-52%	-$935K	﹤0.01%	5363
2018 Q3	$2.32M	Sell	50,400 -22,400	-31%	-$996K	﹤0.01%	3762
2018 Q2	$2.72M	Sell	72,800 -12,900	-15%	-$436K	﹤0.01%	3520
2018 Q1	$2.53M	Buy	85,700 +42,600	+99%	+$1.44M	﹤0.01%	3503
2017 Q4	$1.48M	Sell	43,100 -47,500	-52%	-$1.6M	﹤0.01%	4485
2017 Q3	$3.28M	Sell	90,600 -87,900	-49%	-$2.51M	﹤0.01%	3098
2017 Q2	$4.61M	Sell	178,500 -4,100	-2%	-$87K	﹤0.01%	2509
2017 Q1	$3.51M	Buy	182,600 +63,400	+53%	+$1.12M	﹤0.01%	2796
2016 Q4	$1.99M	Buy	119,200 +59,000	+98%	+$1.07M	﹤0.01%	4084
2016 Q3	$1.24M	Sell	60,200 -70,400	-54%	-$1.79M	﹤0.01%	4396
2016 Q2	$4M	Sell	130,600 -23,000	-15%	-$799K	﹤0.01%	2500
2016 Q1	$5.75M	Sell	153,600 -34,500	-18%	-$1.3M	﹤0.01%	2127
2015 Q4	$8.12M	Sell	188,100 -16,200	-8%	-$684K	﹤0.01%	1970
2015 Q3	$7.66M	Sell	204,300 -109,600	-35%	-$3.89M	﹤0.01%	2130
2015 Q2	$10.7M	Sell	313,900 -69,700	-18%	-$2.37M	﹤0.01%	1921
2015 Q1	$13.6M	Sell	383,600 -123,700	-24%	-$4.43M	0.01%	1573
2014 Q4	$17.3M	Sell	507,300 -167,000	-25%	-$5.93M	0.01%	1470
2014 Q3	$26M	Sell	674,300 -196,900	-23%	-$7.35M	0.01%	1179
2014 Q2	$33.9M	Sell	871,200 -173,100	-17%	-$6.44M	0.01%	951
2014 Q1	$35.7M	Sell	1,044,300 -896,300	-46%	-$27.8M	0.02%	829
2013 Q4	$40.7M	Buy	1,940,600 +857,900	+79%	+$21.7M	0.02%	792
2013 Q3	$25.4M	Buy	1,082,700 +434,800	+67%	+$12.4M	0.01%	1035
2013 Q2	$17.4M	Buy	+647,900	New	+$18.8M	0.01%	1235

Other funds holding MYGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group's MYGN Position: Q1 2026 in Review

Susquehanna International Group increased its Myriad Genetics (MYGN) stake by 416% in Q1 2026, buying an estimated $1.36M and bringing the position to 323,519 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #6969.

Susquehanna International Group first reported a position in MYGN in Q2 2013 and has held it in 44 quarters since. The position peaked at $12M in Q4 2013. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

Susquehanna International Group held 323,519 shares of Myriad Genetics worth $1.46M as of Q1 2026.
Susquehanna International Group bought 260,841 Myriad Genetics shares in Q1 2026, an estimated $1.36M.
Myriad Genetics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6969 holding.
Susquehanna International Group first reported a position in Myriad Genetics in Q2 2013 and has held it in 44 quarters since.
Susquehanna International Group's Myriad Genetics position peaked at $12M in Q4 2013.
202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.